| Instil Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update |
Enrollment of 1L NSCLC patients in China trial of AXN-2510/IMM2510 in combination with chemotherapy is ongoing with initial clinical data by ImmuneOnco expected in 2H 2025 Initiation of U.S. clinical study of AXN-2510/IMM2510 in combination with chemotherapy in 1L NSCLC anticipated before the end of 2025, assuming receipt of necessary regulatory approvals DALLAS, May 13, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its first quarter 2025 financial results and provided a corporate update. Recent Highlights: ImmuneOnco's Phase 1b/2 trial of AXN-2510/IMM2510 in combination with chemotherapy in 1L NSCLC in China is ongoing and ImmuneOnco anticipates initial clinical data from first-line NSCLC patients in 2H 2025. |
globenewswire.com |
2025-05-13 11:00:00 |
Czytaj oryginał (ang.) |
| Instil Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update |
Clinical data for AXN-2510/IMM2510 monotherapy in relapsed/refractory NSCLC in China by ImmuneOnco, as well as additional safety data in other solid tumors, anticipated in 1H 2025 |
globenewswire.com |
2025-03-04 09:09:00 |
Czytaj oryginał (ang.) |
| Instil Bio Announces Clinical Progress in China for IMM2510/SYN-2510, a Clinical-Stage PD-L1xVEGF Bispecific Antibody |
ImmuneOnco announced dosing of first patient in its recently initiated Phase 1b/2 clinical trial of IMM2510/SYN-2510 in combination with chemotherapy in patients with advanced NSCLC in China |
globenewswire.com |
2025-01-14 09:00:00 |
Czytaj oryginał (ang.) |
| Bullish Outlook On Instil Bio's Investigational Cancer Drug: Jefferies Sees Over 300% Stock Upside |
Jefferies upgraded Instil Bio TIL, noting that 2024 was a banner year for the PD-(L)1xVEGF class. |
benzinga.com |
2025-01-07 16:06:19 |
Czytaj oryginał (ang.) |
| Instil Bio's Strategic Shift To SYN-2510: A Speculative 'Buy' Opportunity |
Instil Bio is a clinical-stage biotech focusing on personalized immunotherapy. SYN-2510 targets the promising PD-L1/VEGF oncology pathway. The company recently licensed assets from ImmuneOnco Biopharmaceuticals, retaining commercialization rights outside Greater China and enhancing its global market positioning. SYN-2510 is advancing to Phase 2 trials for NSCLC and TNBC, addressing a TAM forecasted to reach $43.7 billion by 2026. |
seekingalpha.com |
2024-12-01 07:00:26 |
Czytaj oryginał (ang.) |
| Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting |
Turnstone's next-generation Selected TIL technology is designed to selectively expand the most potent tumor-reactive T cells for treatment of solid tumors Results further support the continued clinical advancement of TIDAL-01, currently being evaluated in Phase 1 trials SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced it will be presenting two posters highlighting preclinical data on methods for TIL selection at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting being held November 6-10, 2024 in Houston, Texas. “We remain confident that delivering a TIL-based product with a higher proportion of tumor-reactive T cells is the key to extending the clinical application of TILs across a broader range of solid tumors,” said David Stojdl, Ph.D. |
globenewswire.com |
2024-11-05 11:01:00 |
Czytaj oryginał (ang.) |
| 2 Stocks Up Over 700% in 2024 That Could Soar Even Further |
Summit Therapeutics' stock is way up in response to clinical trial results that suggest the cancer therapy it's developing could become the standard of care for lots of patients. Instil Bio stock soared because it's developing a bispecific antibody similar to the candidate that pushed up Summit Therapeutics. |
fool.com |
2024-09-25 08:56:00 |
Czytaj oryginał (ang.) |
| Crude Oil Surges Over 1%; Instil Bio Shares Plunge |
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite falling around 1% on Monday. |
benzinga.com |
2024-09-16 16:31:33 |
Czytaj oryginał (ang.) |
| Instil Bio Stock Skyrockets 641% in One Week: Here's Why |
A rival posted encouraging data on a drug that outperformed Keytruda in certain NSCLC patients. TIL licenses a drug candidate that uses a similar mechanism. |
zacks.com |
2024-09-16 16:26:05 |
Czytaj oryginał (ang.) |
| Instil Bio and ImmuneOnco Announce Global Registrational Strategy for PD-L1xVEGF Bispecific Antibody, SYN-2510/IMM2510, in Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer |
DALLAS and SHANGHAI, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL, "Instil") and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX:1541, “ImmuneOnco”) announced today the global registrational strategy for the PD-L1xVEGF bispecific antibody SYN-2510/IMM2510 in combination with chemotherapy in front-line non-small cell lung cancer (NSCLC) and in front-line triple-negative breast cancer (TNBC). |
globenewswire.com |
2024-09-16 10:00:00 |
Czytaj oryginał (ang.) |
| Up More Than 500% in 2024. Can Instil Bio Keep Rocketing Higher? |
Instil Bio is developing a bispecific antibody that strengthens immune responses to solid tumors by simultaneously targeting PD-L1 and VEGF. Instil Bio's lead immunology candidate is still in phase 1 testing, but a similar candidate from Summit Therapeutics recently outperformed Keytruda. |
fool.com |
2024-09-14 08:56:00 |
Czytaj oryginał (ang.) |
| Instil Bio: PD-L1/VEGF Bispecific Targeting With Unique Enhancements |
Instil Bio, Inc. in-licensing brings on board high demand IMM2510 clinical product with PD-L1/VEGF targeting of solid tumors; proof-of-concept established by Summit/Akeso and BioNTech. Two competitive advantages of IMM2510 would be the ability to bind to other VEGF ligands beyond that of VEGF-A only and to have enhanced ADCC killing. In-licensing deal with ImmuneOnco also brings on board next-generation anti-CTLA-4 antibody IMM27M, which also has enhanced ADCC killing. |
seekingalpha.com |
2024-09-13 17:22:55 |
Czytaj oryginał (ang.) |
| Instil Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update |
DALLAS, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its second quarter 2024 financial results and provided a corporate update. |
globenewswire.com |
2024-08-13 21:00:00 |
Czytaj oryginał (ang.) |
| Instil Bio and ImmuneOnco Announce License and Collaboration Agreement for Development of IMM2510, a Potentially Best-in-Class PD-L1xVEGF Bispecific Antibody, and IMM27M, a Novel Next-Generation Anti-CTLA-4 Antibody |
DALLAS and SHANGHAI, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL, “Instil”) and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX Code: 1541.HK, “ImmuneOnco”), today announced a definitive agreement pursuant to which Instil is in-licensing ex-China development and commercial rights to ImmueOnco's proprietary PD-L1xVEGF bispecific antibody, IMM2510, as well as its next-generation anti-CTLA-4 antibody, IMM27M. |
globenewswire.com |
2024-08-01 10:00:00 |
Czytaj oryginał (ang.) |
| Q2 2024 Earnings Estimate for Precision BioSciences, Inc. (NASDAQ:DTIL) Issued By HC Wainwright |
Precision BioSciences, Inc. (NASDAQ:DTIL – Free Report) – Research analysts at HC Wainwright raised their Q2 2024 earnings estimates for shares of Precision BioSciences in a note issued to investors on Wednesday, May 15th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings per share of ($0.77) for the quarter, up from their prior estimate of ($1.26). HC Wainwright currently has a “Buy” rating and a $60.00 price target on the stock. HC Wainwright also issued estimates for Precision BioSciences’ Q3 2024 earnings at ($0.79) EPS, Q4 2024 earnings at ($0.43) EPS, Q1 2025 earnings at ($0.39) EPS, Q2 2025 earnings at ($0.07) EPS, Q3 2025 earnings at ($0.33) EPS, Q4 2025 earnings at ($0.26) EPS and FY2025 earnings at ($1.06) EPS. Precision BioSciences (NASDAQ:DTIL – Get Free Report) last announced its quarterly earnings data on Wednesday, March 27th. The company reported ($3.35) earnings per share (EPS) for the quarter, missing the consensus estimate of $3.00 by ($6.35). The firm had revenue of $7.04 million during the quarter, compared to the consensus estimate of $28.50 million. Precision BioSciences had a negative return on equity of 131.69% and a negative net margin of 48.10%. Separately, Guggenheim assumed coverage on shares of Precision BioSciences in a research note on Tuesday, April 30th. They set a “buy” rating and a $19.00 price target for the company. Read Our Latest Report on DTIL Precision BioSciences Price Performance Shares of NASDAQ DTIL opened at $12.40 on Monday. The company has a market cap of $85.93 million, a P/E ratio of -1.66 and a beta of 1.62. Precision BioSciences has a 1 year low of $8.25 and a 1 year high of $27.02. The firm has a 50-day simple moving average of $11.96 and a two-hundred day simple moving average of $11.98. Institutional Trading of Precision BioSciences A number of institutional investors and hedge funds have recently modified their holdings of DTIL. Curi Wealth Management LLC increased its stake in shares of Precision BioSciences by 42.0% during the third quarter. Curi Wealth Management LLC now owns 339,801 shares of the company’s stock worth $116,000 after purchasing an additional 100,530 shares in the last quarter. Tejara Capital Ltd increased its stake in shares of Precision BioSciences by 100.7% during the third quarter. Tejara Capital Ltd now owns 398,614 shares of the company’s stock worth $136,000 after purchasing an additional 200,000 shares in the last quarter. Acadian Asset Management LLC increased its stake in shares of Precision BioSciences by 8.3% during the third quarter. Acadian Asset Management LLC now owns 3,148,243 shares of the company’s stock worth $1,073,000 after purchasing an additional 242,425 shares in the last quarter. Finally, Janus Henderson Group PLC purchased a new stake in shares of Precision BioSciences during the first quarter worth about $7,739,000. Hedge funds and other institutional investors own 37.99% of the company’s stock. Precision BioSciences Company Profile (Get Free Report) Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. See Also Five stocks we like better than Precision BioSciences Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time MarketBeat Week in Review – 5/13 – 5/17 Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed Take-Two Interactive Software Offers 2nd Chance for Investors The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number Deere & Company’s Q2 Report: Strong Revenue, Cautious Outlook |
https://www.defenseworld.net |
2024-05-20 05:38:49 |
Czytaj oryginał (ang.) |
| Instil Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update |
DALLAS, May 10, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its first quarter 2024 financial results and provided a corporate update. |
globenewswire.com |
2024-05-10 11:00:00 |
Czytaj oryginał (ang.) |
| What Makes Instil Bio (TIL) a New Buy Stock |
Instil Bio (TIL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2024-03-27 15:01:15 |
Czytaj oryginał (ang.) |
| Instil Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update |
DALLAS, March 21, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its fourth quarter and full year 2023 financial results and provided a corporate update. |
globenewswire.com |
2024-03-21 19:00:00 |
Czytaj oryginał (ang.) |
| Instil (TIL) Stock Rises More Than 20% in a Week: Here's Why |
Instil's (TIL) recent deal with a collaborator to carry out preclinical manufacturing feasibility studies on its ITIL-306 program is a positive. |
zacks.com |
2024-01-18 15:32:06 |
Czytaj oryginał (ang.) |
| Instil Bio Announces Strategic Update |
DALLAS, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil” or the “Company”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today announced a strategic update. |
globenewswire.com |
2024-01-16 10:00:00 |
Czytaj oryginał (ang.) |
| Instil Bio Announces Effective Date of 1-for-20 Reverse Stock Split |
DALLAS, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil” or the “Company”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today announced that a 1-for-20 reverse stock split of its outstanding shares of common stock will be effective as of 5:00 p.m. Eastern Time on Thursday, December 7, 2023. |
globenewswire.com |
2023-12-05 19:00:00 |
Czytaj oryginał (ang.) |
| Instil Bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update |
DALLAS, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today reported its third quarter 2023 financial results and provided a corporate update. |
globenewswire.com |
2023-11-13 19:00:00 |
Czytaj oryginał (ang.) |
| Instil Bio Announces Poster Presentations of ITIL-306 Preclinical Data at SITC 2023 Annual Meeting |
Presented novel preclinical data showing that CoStAR enhances activity of CD4+ T cells in multiple ways to broaden anti-tumor response and support CD8+ T cells Presented novel preclinical data showing that CoStAR enhances activity of CD4+ T cells in multiple ways to broaden anti-tumor response and support CD8+ T cells |
globenewswire.com |
2023-11-06 09:00:00 |
Czytaj oryginał (ang.) |
| After Plunging -18.52% in 4 Weeks, Here's Why the Trend Might Reverse for Instil Bio, Inc. (TIL) |
The heavy selling pressure might have exhausted for Instil Bio, Inc. (TIL) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal. |
zacks.com |
2023-08-31 15:18:10 |
Czytaj oryginał (ang.) |